Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine

Claire I. Daïen; Jacques Morel

doi:10.1155/2014/386148

journal article Open Access Jan 01, 2014

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine

Claire I. Daïen Jacques Morel

Mediators of Inflammation Vol. 2014 pp. 1-11 · Wiley

View at Publisher Save 10.1155/2014/386148

Abstract

Many therapies are now available for patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate including tumor necrosis factor inhibitors, abatacept, tocilizumab, and rituximab. Clinical response to drugs varies widely between individuals. A part of this variability is due to the characteristics of the patient such as age, gender, concomitant therapies, body mass index, or smoking status. Clinical response also depends on disease characteristics including disease activity and severity and presence of autoantibodies. Genetic background, cytokine levels, and immune cell phenotypes could also influence biological therapy response. This review summarizes the impact of all those parameters on response to biological therapies.

Topics

No keywords indexed for this article. Browse by subject →

References

62

[1]

10.1136/annrheumdis-2011-201225

[2]

10.1136/annrheumdis-2012-202184

[3]

10.1371/journal.pone.0061045

[4]

10.1002/art.24721

[5]

10.1186/ar1465

[6]

10.1186/ar3431

[7]

10.1007/s00296-011-2033-5

[8]

10.1002/art.23247

[9]

10.1002/art.23141

[10]

10.1002/art.21830

[11]

10.1093/rheumatology/ken002

[12]

10.1007/s10165-010-0366-7

[13]

10.1136/ard.2010.140129

[14]

10.1136/annrheumdis-2011-201109

[15]

10.3899/jrheum.110610

[16]

10.1002/art.30136

[17]

10.1002/acr.21768

[18]

10.1093/rheumatology/kel149

[19]

10.1097/rhu.0b013e3181ca4a2a

[20]

10.1093/rheumatology/kes184

[21]

10.1002/art.27758

[22]

Clinical and Experimental Rheumatology (2010)

[23]

10.1002/art.22120

[24]

10.1136/ard.2008.102244

[25]

10.3899/jrheum.110410

[26]

Clinical and Experimental Rheumatology (2005)

[27]

10.1016/j.jcin.2011.09.027

[28]

10.1136/annrheumdis-2012-202220

[29]

10.1136/ard.2010.148759

[30]

10.1093/rheumatology/kep314

[31]

10.1136/ard.2007.084715

[32]

10.1016/j.semarthrit.2012.11.007

[33]

10.1136/ard.2008.092833

[34]

10.1136/ard.2006.065615

[35]

10.1136/annrheumdis-2011-200184

[36]

10.1093/rheumatology/ker124

[37]

10.1002/art.20019

[38]

10.3899/jrheum.111522

[39]

10.1136/ard.2010.135111

[40]

10.1002/art.11168

[41]

10.1002/art.27457

[42]

10.1002/art.33381

[43]

10.1002/art.30130

[44]

10.1136/annrheumdis-2011-200337

[45]

10.1136/annrheumdis-2012-202435

[46]

10.1182/blood.v99.3.754

[47]

Clinical and Experimental Rheumatology (2013)

[48]

10.1093/rheumatology/kes094

[49]

10.1136/ard.2007.080440

[50]

10.3899/jrheum.110697

Showing 50 of 62 references

Metrics

52

Citations

62

References

Details

Published: Jan 01, 2014
Vol/Issue: 2014
Pages: 1-11
License: View

Authors

C

Claire I. Daïen

Department of Rheumatology, Lapeyronie Hospital, University Montpellier I-II and IGMM-UMR5535, CNRS 1919, Route de Mende, 34295 Montpellier Cedex 5, France

J

Jacques Morel

Department of Rheumatology, Lapeyronie Hospital, University Montpellier I-II and IGMM-UMR5535, CNRS 1919, Route de Mende, 34295 Montpellier Cedex 5, France

Cite This Article

Claire I. Daïen, Jacques Morel (2014). Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine. Mediators of Inflammation, 2014, 1-11. https://doi.org/10.1155/2014/386148

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine

You May Also Like